Clinical Trial Update: Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects [Phase 3]

View source ↗

Summary

Phase 3 study comparing once-daily versus twice-daily lopinavir/ritonavir in ART-experienced HIV-1 infected subjects coadministered with nucleoside/nucleotide r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Kaletra (lopinavir)

Snippet

Sponsor: Abbott | Conditions: Human Immunodeficiency Virus Infections | Phase 3 | Status: COMPLETED | Results posted: 2010-02-01